Utilizing SBIRI funding, Mediclone Biotech has successfully created
monoclonal immuno-phenotyping kits for human red blood cells
In a situation where a person is in a dire need of blood, the right
blood group is vital for saving the person's life. In such a situation,
a tool that identifies blood groups immediately can play a life saving
role. Chennai-based biotech company, Mediclone Biotech, has developed a
diagnostic kit that can help in determining the patient's blood group
instantly. Mediclone Biotech has developed bioprocess methods and
control systems to produce monoclonal immuno-phenotyping kits for human
red blood cells.
The infrastructure required to develop bioprocess methods and systems
were partly funded by the Department of Biotechnology (DBT) through the
Small Business Innovation Research Initiative (SBIRI) scheme. With the
SBIRI funding, the pilot scale manufacturing of the product was
completed in September 2009. The immuno-phenotyping kits could be
effectively used in blood banks and clinical labs to categorize blood.
Started in 1995 as a maiden biotech venture by first generation
entrepreneurs, Mediclone Biotech is a privately-owned biotech company
specializing in immunobiotechnology. Today, Mediclone Biotech has
state-of-the-art infrastructure comprising biopharma production plant
with cGMP compliance, quality control and quality assurance; in-house
R&D; and in-plant education and training facilities.
SBIRI scheme was vital for Mediclone Biotech to continue the project.
This would have not been possible without venture capital funding.
SBIRI scheme eased out the stress of entrepreneurs and gave the company
confidence to carry out R&D activities.
The PPP project has been a great success and the significant results
have been achieved. Therefore, the company, while utilizing the funding
has been able to create a positive impact on the industry. In October
2009, Mediclone launched fully-indigenous monoclonal antibodies to
human red blood cell phenotyping. Currently, these products are being
marketed to Tamil Nadu Medical Supplies Corporation, Government of
Tamil Nadu, and AIDS Control Society in India. Besides that, the
product is also being exported to China, Myanmar, Bangladesh,
Indonesia, Africa, Iraq, UAE and many other countries.
Diagnostic Biomedicine was the start-up for the company. Over the
period of time, a range of diagnostically significant monoclonal
antibody-based kits have been developed and marketed. The company is
currently working on therapeutic bio-molecules for infectious diseases
and snake toxins. In the year 2010-11, the company expects $2 million (
10 crore ) in revenues with 30 percent
growth in the subsequent years.
in New Delhi